Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-191.33M |
| Operating Margin | 0.00% |
| Return on Equity | -42.90% |
| Return on Assets | -25.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.88 |
| Price-to-Book | 2.49 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -3.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $87.35M |
| Float | $59.37M |
| % Insiders | 1.80% |
| % Institutions | 119.37% |
Volatility is currently expanding